Last updated: July 26, 2026
Executive summary: Celgene’s infringement case against Mylan in 1:20-cv-00003 is a federal Hatch-Waxman patent litigation focused on Orange Book-listed IP for Celgene’s product (the asserted patents and case posture cannot be reliably stated from the provided identifier alone). Without the complaint/docket record and asserted patent list, a complete, accurate litigation summary and infringement/validity analysis cannot be produced.
What is the litigation timeline for Celgene v. Mylan Pharmaceuticals Inc. 1:20-cv-00003?
Answer: Not determinable from the case caption/number alone.
Key docket events likely tracked in this matter
- Complaint filing date and venue
- Patent list in the complaint (asserted US patents)
- Motion practice schedule (Rule 12, claim construction, summary judgment)
- Scheduling order milestones (Markman, expert reports, trial dates)
- Any stay events tied to PTAB (if invoked) or parallel FDA regulatory actions
- Disposition status (dismissal, settlement, final judgment, or ongoing briefing)
Which patents were asserted in Celgene v. Mylan (1:20-cv-00003)?
Answer: Not determinable from the provided identifier alone.
What to extract from the docket to identify the asserted estate
- Title/claims of each asserted patent
- Patent numbers and assignees (Celgene, Bristol Myers Squibb, or others)
- Whether patents include:
- composition-of-matter
- formulation
- method-of-use
- manufacturing method
- Whether claims track specific dosages (tablet strength, daily regimen, formulation type)
What is Celgene’s infringement theory versus Mylan’s proposed ANDA in this case?
Answer: Not determinable from the provided identifier alone.
Typical infringement theory elements in Hatch-Waxman cases
- Claim construction targets (what the court defines for key claim terms)
- Mapping of Mylan’s product characteristics to each asserted claim
- Use of ANDA drug product data (e.g., label, formulation, specs)
- Contentions on literal infringement and/or doctrine of equivalents
How does Mylan defend against Celgene’s claims (non-infringement, invalidity, unenforceability)?
Answer: Not determinable from the provided identifier alone.
Invalidity and unenforceability themes to check
- §102 novelty and §103 obviousness grounds
- §112 definiteness and enablement
- Written description / best mode (where applicable)
- Inequitable conduct allegations (if pled)
- Priority disputes (earlier priority date vs. prior art)
- Prosecution history estoppel and claim scope limits
What did the court decide in the Celgene v. Mylan case (motions, claim construction, summary judgment)?
Answer: Not determinable from the provided identifier alone.
How to evaluate decision impact
- Whether the court construed claim terms narrowly or broadly
- Whether the court granted dispositive motions (invalidity/non-infringement)
- Whether any claims were dropped or narrowed post-construction
- Whether an exclusivity or FDA regulatory posture affects infringement analysis
How does this litigation affect FDA approval timelines and generic entry risk for Celgene’s product?
Answer: Not determinable from the provided identifier alone.
Entry-risk drivers to map to docket outcomes
- Whether a Paragraph IV certification triggered the filing stay
- Whether the case settled (and on what terms)
- Whether a final judgment enabled earlier launch
- Whether Mylan’s ANDA was withdrawn/amended during litigation
What settlement terms or endgame outcomes are linked to 1:20-cv-00003?
Answer: Not determinable from the provided identifier alone.
Settlement artifacts to confirm
- Joint stipulation of dismissal with or without prejudice
- Launch/temporary supply or “carve-out” agreements
- Design-around commitments tied to specific claims
- Covenant not to sue scope (patents covered, jurisdictions)
What is the Orange Book status of Celgene’s asserted product(s) in this dispute?
Answer: Not determinable from the provided identifier alone.
Orange Book mapping required for litigation alignment
- List of patents by submission (drug and NDA reference)
- Patent expiration dates and pediatric exclusivity-adjusted dates
- Whether the asserted patents are listed for:
- drug substance
- drug product
- method-of-use
- Which patents correlate to each count in the complaint
How strong is Celgene’s patent estate in this specific dispute?
Answer: Not determinable from the provided identifier alone.
Strength scoring inputs that require docket-specific facts
- Count-level validity likelihood based on prior art set
- Claim construction outcomes
- Evidence of commercial manufacture and infringement proof standards
- Whether patents are formulation- or method-dependent (often more vulnerable to design-arounds)
Which competitors besides Mylan face similar Celgene patent exposure (and how do their strategies compare)?
Answer: Not determinable from the provided identifier alone.
Comparison requires verified asserted-patent and product identity
- Other ANDA filers challenging the same Orange Book patents
- Settlement patterns among co-litigants
- Differences in proposed dosage form (tablet vs. oral suspension, etc.)
- Timing of Paragraph IV notices and first generics entry
Key takeaways
Answer: A factual, litigation-ready summary cannot be generated from case number alone. Producing an accurate summary requires the complaint and docket record showing: asserted patents, asserted claims, Mylan’s ANDA/product description used for infringement contentions, the specific court decisions or settlement posture, and the resulting FDA launch constraints.
FAQs
Answer: No factual responses can be provided without the docket and complaint content for 1:20-cv-00003.
